カテゴリ： GlobalData, 企業調査, 日本

Sumitomo Dainippon Pharma Co Ltd (4506)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Sumitomo Dainippon Pharma Co Ltd (4506) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10088
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：136
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd (4506) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19
Venture Financing 21
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22
Matrizyme Pharma Raises USD9 Million in Financing 23
Tolero Pharma Raises US$3.33 Million In Venture Financing 24
Elevation Pharma Secures US$30 Million In Series B Financing 25
Private Equity 27
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27
Partnerships 28
Tolero Pharma Enters into Research Agreement with AbbVie 28
Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30
Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32
Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34
FunPep Enters into Research Agreement with Sumitomo Dainippon 35
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37
Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38
ex scientia Enters into Research Agreement with Sunovion Pharma 39
Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40
Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43
Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45
Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48
Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50
Licensing Agreements 51
Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53
Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55
Sunovion Pharma Enters into Licensing Agreement with Novartis 56
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59
SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62
Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65
Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69
Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 73
Equity Offering 74
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 78
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 79
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 81
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 82
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 83
Debt Offering 84
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 84
Asset Transactions 86
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87
Acquisition 88
Sumitomo Dainippon Pharma Acquires Tolero Pharma 88
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90
Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For US$16 Million 92
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 93
Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95
Sumitomo Dainippon Pharma Co Ltd – Key Competitors 97
Sumitomo Dainippon Pharma Co Ltd – Key Employees 98
Sumitomo Dainippon Pharma Co Ltd – Locations And Subsidiaries 100
Head Office 100
Other Locations & Subsidiaries 100
Recent Developments 103
Strategy And Business Planning 103
Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 103
Financial Announcements 104
Oct 30, 2018: Sumitomo Dainippon: Consolidated financial results for the second quarter of the year ending March 31, 2019 104
Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 107
May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 110
Corporate Communications 115
Sep 03, 2018: Sumitomo Dainippon Pharma announces personnel changes 115
Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 116
Jun 15, 2018: Sumitomo Dainippon Pharma Announces Management Changes 117
May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 118
Feb 23, 2018: Sumitomo Dainippon Pharma Names Hiroshi Nomura As President And CEO 119
Mar 29, 2017: Sumitomo Dainippon Pharma announces Changes in Executive Officers 120
Mar 22, 2017: Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical and Establishment of Global Head of Oncology 121
Legal and Regulatory 123
Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson’s disease 123
Government and Public Interest 124
Jun 01, 2017: Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period 124
Product News 125
05/17/2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018 125
Product Approvals 126
Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome 126
Feb 28, 2017: Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a “SAKIGAKE” Product by Japan’s Ministry of Health, Labour and Welfare 127
Clinical Trials 128
Jul 31, 2018: Kyoto University to begin trials of iPS cells to treat Parkinson’s 128
Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018 129
Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) 130
Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 131
May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 132
Other Significant Developments 133
May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma - Sumitomo Dainippon Pharma Co Ltd] 133
Jul 04, 2017: Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S. 134
Apr 10, 2017: Hitachi is selected by Sumitomo Dainippon Pharma for Automated Cell Mass Culture Equipment for Regenerative Medicine using Human iPS Cells 135
Appendix 136
Methodology 136
About GlobalData 136
Contact Us 136
Disclaimer 136

List of Tables
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22
Matrizyme Pharma Raises USD9 Million in Financing 23
Tolero Pharma Raises US$3.33 Million In Venture Financing 24
Elevation Pharma Secures US$30 Million In Series B Financing 25
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27
Tolero Pharma Enters into Research Agreement with AbbVie 28
Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30
Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32
Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34
FunPep Enters into Research Agreement with Sumitomo Dainippon 35
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37
Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38
ex scientia Enters into Research Agreement with Sunovion Pharma 39
Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40
Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43
Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45
Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48
Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50
Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53
Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55
Sunovion Pharma Enters into Licensing Agreement with Novartis 56
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59
SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62
Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65
Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69
Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 73
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 78
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 79
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 81
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 82
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 83
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 84
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87
Sumitomo Dainippon Pharma Acquires Tolero Pharma 88
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90
Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For US$16 Million 92
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 93
Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95
Sumitomo Dainippon Pharma Co Ltd, Key Competitors 97
Sumitomo Dainippon Pharma Co Ltd, Key Employees 98
Sumitomo Dainippon Pharma Co Ltd, Other Locations 100
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101

List of Figures
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Sumitomo Dainippon Pharma Co Ltd (4506)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • 4D Molecular Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary 4D Molecular Therapeutics Inc (4D Molecular Therapeutics) is a gene therapy company that deliver genes to specific cells in the body to eradicate rare and large market diseases. The company discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. It …
  • Blade Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Blade Therapeutics Inc (Blade Therapeutics) is a biopharmaceutical company which develops novel anti-fibrotic therapies to treat various fibrotic disorders. Its lead program is a small molecule inhibitor targeting an intracellular cysteine protease associated with fibrosis across diverse ind …
  • Adams Rite Aerospace, Inc.：企業の戦略・SWOT・財務情報
    Adams Rite Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report Summary Adams Rite Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Florida Public Utilities Co：企業の戦略的SWOT分析
    Florida Public Utilities Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Bank of Ayudhya Public Co Ltd (BAY)：企業の財務・戦略的SWOT分析
    Bank of Ayudhya Public Co Ltd (BAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Peet’s Coffee & Tea Inc：企業の戦略・SWOT・財務情報
    Peet's Coffee & Tea Inc - Strategy, SWOT and Corporate Finance Report Summary Peet's Coffee & Tea Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • SeaSpine Holdings Corporation (SPNE)：企業の財務・戦略的SWOT分析
    SeaSpine Holdings Corporation (SPNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • PHX Energy Services Corp (PHX)：企業の財務・戦略的SWOT分析
    Summary PHX Energy Services Corp (PHX Energy), formerly Phoenix Technology Income Fund is an energy service company that manufactures, designs, and engineers directional drilling technologies. The corporation’s equipment includes RADD, P-360 MWD, 360-CV MWD, E-360 MWD, 360 RWD, and performance motor …
  • QuikTrip Corporation：企業の戦略的SWOT分析
    QuikTrip Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • EXINI Diagnostics AB：医療機器：M&Aディール及び事業提携情報
    Summary EXINI Diagnostics AB (EXINI), a subsidiary of Progenics Pharmaceuticals Inc, is a healthcare technology company that offers development of software solutions for the medical diagnostic market. The company offers aBSI, a web application used by trained healthcare professionals and researchers …
  • Sierra Oncology Inc (SRRA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small mo …
  • Heartland Consumers Power District：企業の戦略的SWOT分析
    Heartland Consumers Power District - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Tishman Realty & Construction Co., Inc.：企業の戦略・SWOT・財務情報
    Tishman Realty & Construction Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Tishman Realty & Construction Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Advent Capital (Holdings) Ltd：企業の戦略・SWOT・財務情報
    Advent Capital (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Advent Capital (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Tohoku Electric Power Co Inc (9506)：企業の財務・戦略的SWOT分析
    Tohoku Electric Power Co Inc (9506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • SKY Network Television Limited (SKT)：企業の財務・戦略的SWOT分析
    SKY Network Television Limited (SKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • CGI Group Inc.：企業の戦略・SWOT・財務情報
    CGI Group Inc. - Strategy, SWOT and Corporate Finance Report Summary CGI Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • CITIC Resources Holdings Limited：戦略・SWOT・企業財務分析
    CITIC Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • International Frontier Resources Corp (IFR)：石油・ガス：M&Aディール及び事業提携情報
    Summary International Frontier Resources Corp (IFR) is an oil and gas company. The company explores and develops oil and natural gas properties in Mexico, Canada and the US. Its projects include Canol and Bluefish Shale oil plays, Summit creek and Stewart Lake project, EL-495, and TDL M-37 and M-38. …
  • Pfizer Inc (PFE)：医療機器：M&Aディール及び事業提携情報
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆